RT Journal Article
SR Electronic
T1 Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 956
OP 960
DO 10.2967/jnumed.120.245290
VO 62
IS 7
A1 Dong-Yeon Kim
A1 Ayoung Pyo
A1 Misun Yun
A1 Ramar Thangam
A1 Sung-Hwan You
A1 Ying Zhang
A1 Ye-rim Jung
A1 Dinh-Huy Nguyen
A1 Akhil Venu
A1 Hyeon Sik Kim
A1 Mee Sun Yoon
A1 Yeongjin Hong
A1 Jung-Joon Min
YR 2021
UL http://jnm.snmjournals.org/content/62/7/956.abstract
AB Surface-exposed calreticulin (ecto-CRT) is a well-known “eat-me” signal exhibited by dying cells that contributes to their recognition and destruction by the immune system. We assessed the use of a CRT-specific binding peptide for imaging ecto-CRT during immunogenic cell death and its utility for early prediction of treatment response. Methods: A synthetic CRT-specific peptide, KLGFFKR (CRTpep), was labeled with fluorescein isothiocyanate or 18F, and the characteristics of ecto-CRT were evaluated in a colon cancer cell line in vitro and in vivo. Results: In vitro flow cytometry, immunofluorescence staining, and in vivo small-animal PET imaging results showed that CRTpep detected preapoptotic cells treated with immunogenic drugs or radiation but not those treated with the nonimmunogenic drug or a nontherapeutic dose of immunogenic drug. Conclusion: The present results indicate that the CRT-specific peptide would enable the prediction of therapeutic response, thereby facilitating early decisions on continuation or discontinuation of immunogenic treatment.